This fact is in contradiction with previous studies that incriminate the role of cannabinoids and, more precisely, the activation of CB1 and CB2 receptors, respectively, and of probably other yet unidentified receptors, in the pathogenic chain of hepatic steatosis and non-alcoholic fatty liver [58,59,60]. The gene discussed is CNR1; the disease is fatty liver disease.